Adaptimmune Therapeutics PLC at JPMorgan Healthcare Conference (Virtual) Transcript
Good morning, everyone. Thank you for joining. My name is Michael Klem. I'm a member of JPMorgan's health care investment banking team. It's my pleasure to introduce Adrian Rawcliffe and Elliot Norry, the CEO and CMO of Adaptimmune.
Quick housekeeping note. If you would like to submit a question, there's a button, ask a question feature underneath the presentation. Without further ado, I'll turn it over to you, Adrian, to kick us off. Thanks.
Thanks, Michael. people ask me what makes Adaptimmune different? Why are you built in the way that you are? Why do you do the things the way that you do them? And the answer is that Adaptimmune is different because cell therapy is different. Cell therapy is personal. When a person with cancer decides to be treated with our autologous SPEAR T-cells they give a part of themselves to us, they entrust us with their white blood cells. A part of that patient, a part of that person comes into our facility. It comes
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
